Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
2006 StandoutScience
Effective expansion of alloantigen-specific Foxp3 + CD25 + CD4 + regulatory T cells by dendritic cells during the mixed leukocyte reaction
2006 StandoutNobel
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
1995
CD4+ Tregs and immune control
2004 StandoutNobel
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Re-establishing immunological self-tolerance in autoimmune disease
2012 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Progress in human tumour immunology and immunotherapy
2001 Nature
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Inflammation and cancer
2002 StandoutNature
Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes
1996
Pathways of T‐cell regeneration in mice and humans: implications for bone marrow transplantation and immmunotherapy
1997
The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases
1993 StandoutNature
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
2000
Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1
2007 StandoutNatureNobel
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Reshaping human antibodies for therapy
1988 StandoutNatureNobel
The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy
2015
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self
2005 StandoutNobel
Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
2009 StandoutNobel
Chimeric antigen receptors: driving immunology towards synthetic biology
2016
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
2008
Unrelated umbilical cord blood transplants in adults: Early recoveryof neutrophils by supportive co-transplantation of a low number of highlypurified peripheral blood CD34+ cells from an HLA-haploidentical donor
2003
Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated Donors
1998 Standout
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
2001 StandoutNobel
Chronic immune activation and inflammation in the pathogenesis of aids and cancer
2002
Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells
2004 StandoutNobel
Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New Vectors
1998
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
2003
Hematopoietic Stem-Cell Transplantation
2006 Standout
Inflammation and cancer: back to Virchow?
2001 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor
2018
FOXP3+ regulatory T cells in the human immune system
2010 StandoutNobel
Points of control in inflammation
2002 StandoutNature
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
1995 Standout
National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States
2005
Changes in thymic function with age and during the treatment of HIV infection
1998 StandoutNature
Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
2005
Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy
1995
A critical role for neutralizing-antibody-producing B cells, CD4+T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
1997
A protective human monoclonal IgA antibody produced in vitro: Anti‐pneumococcal antibody engendered by Epstein‐Barr virus‐immortalized cell line
1986
Reshaping Human Antibodies: Grafting an Antilysozyme Activity
1988 StandoutScienceNobel
Naturally Arising CD4+Regulatory T Cells for Immunologic Self -Tolerance and Negative Control of Immune Responses
2003 StandoutNobel
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
1997 Science
Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells
2002
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients
1998
Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated Diseases
2000
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
CYTOMEGALOVIRUS
1994
High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens
2003
Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34 + Cells with Epstein-Barr Virus
2004
The origin of FOXP3-expressing CD4+ regulatory T cells: thymus or periphery
2003 StandoutNobel
Bone Marrow Transplants from HLA-Identical Siblings as Compared with Chemotherapy for Children with Acute Lymphoblastic Leukemia in a Second Remission
1994
A review of archival auditing research
2014 Standout
Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines
2005
HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTION
1997
VENO-OCCLUSIVE DISEASE OF THE LIVER
1955
Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
2009
Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease
1991
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group
2007
Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation
1991
Vigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
1997 StandoutScience
A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants
1991
Bone Marrow Transplant
1990 Standout
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some Answers
1998
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients
1998
Metal–Organic Frameworks in Biomedicine
2011 Standout
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens [see comments]
1990
Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells
2002
Tolerogenic Dendritic Cells
2003 StandoutNobel
Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? [see comments]
1994
Human Cd4+ T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen Ebna1
2000 StandoutNobel
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Phylogenetic Perspectives in Innate Immunity
1999 StandoutScienceNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
2002
Cloning immunoglobulin variable domains for expression by the polymerase chain reaction.
1989 StandoutNobel
Human lymphocyte Hybridomas and Monoclonal Antibodies
1986
LPS-binding proteins and receptors
1998
Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte Responses Using Dendritic Cells Pulsed With EBNA-3A Peptides or UV-Inactivated, Recombinant EBNA-3A Vaccinia Virus
1999 StandoutNobel
A multiinstitutional survey of the Wiskott-Aldrich syndrome
1994
Works of David Emanuel being referenced
Transjugular intrahepatic portosystemic shunting (TIPS) for treatment of severe hepatic veno-occlusive disease.
1996
Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome
1991
Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow Transplantation
1994
Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin
1988
Allogeneic Bone Marrow Transplantation after Hyperfractionated Total-Body Irradiation and Cyclophosphamide in Children with Acute Leukemia
1987
INTERSTITIAL PNEUMONITIS IN BONE MARROW TRANSPLANT RECIPIENTS IS ASSOCIATED WITH LOCAL PRODUCTION OF TH2-TYPE CYTOKINES AND LACK OF T CELL-MEDIATED CYTOTOXICITY1
1997
Are the Reputations of the Large Accounting Firms Really International? Evidence from the Andersen-Enron Affair
2009
Unrelated placental blood for bone marrow reconstitution: organization of the placental blood program.
1994
A human monoclonal antibody to cytomegalovirus (CMV).
1984
High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments
1998
Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation
2000
The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome
1997
Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation
2000
Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies
2005